Material Safety Data Sheet

2-Chloro-2’-deoxyadenosine
sc-202399

Hazard Alert Code Key:  
- EXTREME
- HIGH
- MODERATE
- LOW

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME
2-Chloro-2’-deoxyadenosine

STATEMENT OF HAZARDOUS NATURE

NFPA

SUPPLIER
Santa Cruz Biotechnology, Inc.
2145 Delaware Avenue
Santa Cruz, California 95060
800.457.3801 or 831.457.3800

EMERGENCY:
ChemWatch
Within the US & Canada: 877-715-9305
Outside the US & Canada: +800 2436 2255
(1-800-CHEMCALL) or call +613 9573 3112

SYNONYMS

Section 2 - HAZARDS IDENTIFICATION

CHEMWATCH HAZARD RATINGS

<table>
<thead>
<tr>
<th></th>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flammability:</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Toxicity:</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Body Contact:</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Reactivity:</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Chronic:</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

CANADIAN WHMIS SYMBOLS

- Min/Nil=0
- Low=1
- Moderate=2
- High=3
- Extreme=4
EMERGENCY OVERVIEW

RISK
Possible risk of harm to the unborn child.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED
- Accidental ingestion of the material may be damaging to the health of the individual.
- The killing action of antineoplastic drugs used for cancer chemotherapy is not selective for cancerous cells alone but affect all dividing cells. Acute side effects include loss of appetite, nausea and vomiting, allergic reaction (skin rash, itch, redness, low blood pressure, unwellness and anaphylactic shock) and local irritation.

EYE
- Although the material is not thought to be an irritant, direct contact with the eye may cause transient discomfort characterized by tearing or conjunctival redness (as with windburn). Slight abrasive damage may also result.

SKIN
- The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.
- Open cuts, abraded or irritated skin should not be exposed to this material.
- Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

INHALED
- The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified using animal models). Nevertheless, adverse effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.
- Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.
- Limited evidence exists that the substance may cause irreversible but non-lethal mutagenic effects following a single exposure.

CHRONIC HEALTH EFFECTS
- Results in experiments suggest that this material may cause disorders in the development of the embryo or fetus, even when no signs of poisoning show in the mother.
  There has been some concern that this material can cause cancer or mutations but there is not enough data to make an assessment.
  Exposure to the material may result in a possible risk of irreversible effects. The material may produce mutagenic effects in man. This concern is raised, generally, on the basis of appropriate studies with similar materials using mammalian somatic cells in vivo. Such findings are often supported by positive results from in vitro mutagenicity studies.
  Anti-cancer drugs used for chemotherapy can depress the bone marrow with reduction in the number of white blood cells and platelets and bleeding. Susceptibility to infections and bleeding is increased, which can be life-threatening.
  Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5 micron penetrating and remaining in the lung.
  CAUTION: May produce immunosuppression in individuals occupationally exposed to the material.
  Exposure to immunosuppressives may aggravate infectious diseases.
  Chronic exposure to therapeutic doses of compounds which produce immunosuppression has been associated with development of lymphomas (occasionally malignant) and mammary tumours. These may be secondary effects induced by activation of endogenous retroviruses.
  Patients on immunosuppressive medications have a 10- to 100-fold increased risk of cancer compared to the general population. Furthermore, people who currently have or have already been treated for cancer have a higher rate of tumor progression and recurrence than patients with an intact immune system.
  Patients receiving immunosuppressive regimens involving combinations of drugs, as part of an immunosuppressive regimen are at increased risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent.
  Increased incidences of neoplasms, in mice and humans, have been reported after long-term immunosuppression by azathioprine and cyclosporin. Cyclosporin has been classified as a human carcinogen, by IARC, based on development of lymphomas after repeated and prolonged exposures to therapeutic doses.
Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>NAME</th>
<th>CAS RN</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-chloro-2'-deoxyadenosine</td>
<td>4291-63-8</td>
<td>&gt;98</td>
</tr>
</tbody>
</table>

Section 4 - FIRST AID MEASURES

**SWALLOWED**
- If swallowed do NOT induce vomiting.
- If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.

**EYE**
- If this product comes in contact with the eyes:
  - Wash out immediately with fresh running water.
  - Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.

**SKIN**
- If skin or hair contact occurs:
  - Flush skin and hair with running water (and soap if available).
  - Seek medical attention in event of irritation.

**INHALED**
- If dust is inhaled, remove from contaminated area.
- Encourage patient to blow nose to ensure clear passage of breathing.
- If irritation or discomfort persists seek medical attention.

**NOTES TO PHYSICIAN**
- Treat symptomatically.
- For employees potentially exposed to antineoplastic and/or cytotoxic agents on a regular basis, a preplacement physical examination and history (noting risk factors) is recommended. Periodic follow-up examinations should also be undertaken and should be overseen by a physician familiar with the toxic effects of the substance and full details of the nature of work undertaken by the employee.
- Elimination is described by a two-compartment, first-order model. 10-30% of the dose appears in the urine within 24 hours. Half-life (alpha) is 3-35 minutes; half-life (beta) 4-14.2 hours.
- Increased serum uric acid levels (hyperuricaemia) may be minimised with hydration and allopurinol. In hospitalised patients, the urine may be alkalised by addition of sodium bicarbonate to IV fluids if tumour lysis is expected. Doses of 0.2 mg/kg/day in adults are associated with severe renal and CNS toxicity.

Section 5 - FIRE FIGHTING MEASURES

**Vapour Pressure (mmHg):** Negligible

**Upper Explosive Limit (%):** Not available.

**Specific Gravity (water=1):** Not available

**Lower Explosive Limit (%):** Not available

**EXTINGUISHING MEDIA**
- Water spray or fog.
- Foam.

**FIRE FIGHTING**
- Alert Emergency Responders and tell them location and nature of hazard.
- Wear breathing apparatus plus protective gloves.

**GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS**
- Combustible solid which burns but propagates flame with difficulty.
- Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust may burn rapidly and fiercely if ignited.
- Combustion products include: carbon monoxide (CO), carbon dioxide (CO2), hydrogen chloride, phosgene, nitrogen oxides (NOx), other pyrolysis products typical of burning organic material.
- May emit poisonous fumes.
- May emit corrosive fumes.

**FIRE INCOMPATIBILITY**
- Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids, chlorine bleaches, pool chlorine etc. as ignition may result.

**PERSONAL PROTECTION**
- Glasses:
- Gloves:
- Respirator:
- Particulate
Section 6 - ACCIDENTAL RELEASE MEASURES

MINOR SPILLS
It is recommended that areas handling final finished product have cytotoxic spill kits available. Spill kits should include:
- impermeable body covering,
- shoe covers,
- latex and utility latex gloves,
- goggles,
- approved HEPA respirator,
- disposable dust pan and scoop,
- absorbent towels,
- spill control pillows,
- disposable sponges,
- sharps container,
- disposable garbage bag and
- hazardous waste label.

To avoid accidental exposure due to waste handling of cytotoxics:
- Place waste residue in a segregated sealed plastic container.
- Used syringes, needles and sharps should not be crushed, clipped, recapped, but placed directly into an approved sharps container.
- Dispose of any cleanup materials and waste residue according to all applicable laws and regulations e.g., secure chemical landfill disposal.
- Clean up waste regularly and abnormal spills immediately.
- Avoid breathing dust and contact with skin and eyes.
- Wear protective clothing, gloves, safety glasses and dust respirator.
- Use dry clean up procedures and avoid generating dust.
- Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
- Dampen with water to prevent dusting before sweeping.
- Place in suitable containers for disposal.

All personnel likely to involved in an antineoplastic (cytotoxic) spill must receive practical training in:
- the correct procedures for handling cytotoxic drugs or waste in order to prevent and minimize the risk of spills
- the location of the skill kit in the area.

MAJOR SPILLS
Moderate hazard.
- CAUTION: Advise personnel in area.
- Alert Emergency Responders and tell them location and nature of hazard.

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING
The National Institute of Health (USA) recommends that the preparation of injectable antineoplastic drugs should be performed in a Class II laminar flow biological safety cabinet and that personnel preparing drugs of this class should wear appropriate personal protective gear. Emphasise controls on containment.
- Avoid all personal contact, including inhalation.
- Wear protective clothing when risk of exposure occurs.

RECOMMENDED STORAGE METHODS
Glass container.
- Polyethylene or polypropylene container.
- Check all containers are clearly labelled and free from leaks.

STORAGE REQUIREMENTS
Antineoplastics (cytotoxics):
- should be clearly identifiable to all personnel involved in their handling
- should be stored in impervious break-resistant containers.
- Store in original containers.
- Keep containers securely sealed.

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

EXPOSURE CONTROLS
The following materials had no OELs on our records
- 2-chloro-2'-deoxyadenosine: CAS:4291-63-8

PERSONAL PROTECTION
RESPIRATOR
Particulate
Consult your EHS staff for recommendations

EYE
- Chemical protective goggles with full seal
- Shielded mask (gas-type)
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lens or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lenses should be removed if the first signs of eye redness or irritation. Lenses should be removed only if a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

HANDS/FEET
- Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:
  - frequency and duration of contact,
  - chemical resistance of glove material,
  - glove thickness and
  - dexterity
- Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).
- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.
- When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.
- Contaminated gloves should be replaced.
- Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturizer is recommended.
- Rubber gloves (nitrile or low-protein, powder-free latex). Employees allergic to latex gloves should use nitrile gloves in preference.
- Double gloving should be considered.
- PVC gloves.
- Protective shoe covers.
- Head covering.
- Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.
  - polychloroprene
  - nitrile rubber
  - butyl rubber
  - fluorocautchouc
  - polyvinyl chloride
- Gloves should be examined for wear and/or degradation constantly.

OTHER
- For quantities up to 500 grams a laboratory coat may be suitable.
- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- Eye wash unit.
- Ensure there is ready access to an emergency shower.
- For Emergencies: Vinyl suit.
- When handling antineoplastic materials, it is recommended that a disposal work-uniform (such as Tyvek or closed front surgical-type gown with knit cuffs) is worn.

ENGINEERING CONTROLS
- Enclosed local exhaust ventilation is required at points of dust, fume or vapor generation.
- HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapors.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL PROPERTIES
Solid. Mixes with water.

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>State</td>
<td>Divided solid</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>285.72</td>
</tr>
<tr>
<td>Melting Range (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>Boiling Range (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>Flash Point (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>Decomposition Temp (°F)</td>
<td>Not available; Viscosity</td>
</tr>
<tr>
<td>Autoignition Temp (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available; Solubility in water (g/L)</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available; pH (1% solution)</td>
</tr>
<tr>
<td>Volatile Component (%vol)</td>
<td>Negligible; pH (as supplied)</td>
</tr>
<tr>
<td>Solubility in water (g/L)</td>
<td>Miscible</td>
</tr>
<tr>
<td>Boiling Range (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>Flash Point (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>Decomposition Temp (°F)</td>
<td>Not available; Viscosity</td>
</tr>
<tr>
<td>Autoignition Temp (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available; Specific Gravity (water=1)</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available; Relative Vapor Density (air=1)</td>
</tr>
<tr>
<td>Volatile Component (%vol)</td>
<td>Negligible; Evaporation Rate</td>
</tr>
<tr>
<td>APPEARANCE</td>
<td>White powder; mixes with water.</td>
</tr>
</tbody>
</table>

**Section 10 - CHEMICAL STABILITY**

**CONDITIONS CONTRIBUTING TO INSTABILITY**
- Presence of incompatible materials.
- Product is considered stable.

**STORAGE INCOMPATIBILITY**
- Avoid reaction with oxidizing agents.

For incompatible materials - refer to Section 7 - Handling and Storage.

**Section 11 - TOXICOLOGICAL INFORMATION**

2-CHLORO-2’-DEOXYADENOSINE

**TOXICITY AND IRRITATION**
2-CHLORO-2’-DEOXYADENOSINE:
- unless otherwise specified data extracted from RTECS - Register of Toxic Effects of Chemical Substances.

<table>
<thead>
<tr>
<th>TOXICITY</th>
<th>IRRITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous (human) TDLo: 0.7 mg/kg/7d-C</td>
<td>Nil Reported</td>
</tr>
<tr>
<td>Intraperitoneal (mouse) LD50: 150 mg/kg</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Substance has been shown to be mutagenic in at least one assay, or belongs to a family of chemicals producing damage or change to cellular DNA.
Dermatitis after systemic exposure, diarrhoea, granulocytopenia have been recorded.
The safe use of this material in pregnancy and its effects on fertility have not been established. Breast feeding is not recommended due to the potential secretion into breast milk.

**Section 12 - ECOLOGICAL INFORMATION**

<table>
<thead>
<tr>
<th>Ecotoxicity</th>
<th>Persistence: Water/Soil</th>
<th>Persistence: Air</th>
<th>Bioaccumulation</th>
<th>Mobility</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-chloro-2’-deoxyadenosine</td>
<td>HIGH</td>
<td>LOW</td>
<td>LOW</td>
<td>HIGH</td>
</tr>
</tbody>
</table>

**Section 13 - DISPOSAL CONSIDERATIONS**

**Disposal Instructions**
All waste must be handled in accordance with local, state and federal regulations.
Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating...
in their area. In some areas, certain wastes must be tracked.
A Hierarchy of Controls seems to be common - the user should investigate:
· Reduction
· Reuse
· Recycling
· Disposal (if all else fails)
This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.
DO NOT allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.
· Antineoplastic (cytotoxic) wastes must be packed directly, ready for incineration, into color-coded, secure, labelled, leak-proof containers sufficiently robust to withstand handling without breaking, bursting or leaking.
· Containers of special design are available for particular needs (such as disposal of sharps) and should be used.

Section 14 - TRANSPORTATION INFORMATION

NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS: DOT, IATA, IMDG

Section 15 - REGULATORY INFORMATION

2-chloro-2'-deoxyadenosine (CAS: 4291-63-8) is found on the following regulatory lists;

Section 16 - OTHER INFORMATION

LIMITED EVIDENCE
■ Ingestion may produce health damage*.
■ Limited evidence of a carcinogenic effect*.
■ Exposure may produce irreversible effects*.
* (limited evidence).

Germany Hazard classification and labelling of medicines with antineoplastic effects (ATC Code L01 and L02)
INN CAS Danger CMR effects CMR effects Other
Cat 1 & Cat 3
Cladribin 4291-63-8 Xn

Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use. For additional technical information please call our toxicology department on +800 CHEMCALL.

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references. A list of reference resources used to assist the committee may be found at: www.chemwatch.net/references.

The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: Jun-29-2007
Print Date: Dec-1-2010